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New-Onset Diabetes in Covid-19
To the Editor: There is a bidirectional relation-
ship between Covid-19 and diabetes. On the one 
hand, diabetes is associated with an increased 
risk of severe Covid-19. On the other hand, new-
onset diabetes and severe metabolic complica-
tions of preexisting diabetes, including diabetic 
ketoacidosis and hyperosmolarity for which ex-
ceptionally high doses of insulin are warranted, 
have been observed in patients with Covid-19.1-3 
These manifestations of diabetes pose challenges 
in clinical management and suggest a complex 
pathophysiology of Covid-19–related diabetes.
Severe acute respiratory syndrome (SARS) 
coronavirus 2 (SARS-CoV-2), the virus that causes 
Covid-19, binds to angiotensin-converting enzyme 
2 (ACE2) receptors, which are expressed in key 
metabolic organs and tissues, including pancre-
atic beta cells, adipose tissue, the small intestine, 
and the kidneys.4 Thus, it is plausible that SARS-
CoV-2 may cause pleiotropic alterations of glucose 
metabolism that could complicate the patho-
physiology of preexisting diabetes or lead to new 
mechanisms of disease.
There are also several precedents for a viral 
cause of ketosis-prone diabetes, including other 
coronaviruses that bind to ACE2 receptors.5 Great-
er incidences of fasting glycemia and acute-onset 
diabetes have been reported among patients with 
SARS coronavirus 1 pneumonia than among those 
with non-SARS pneumonia.5
In the aggregate, these observations provide 
support for the hypothesis of a potential diabeto-
genic effect of Covid-19, beyond the well-recog-
nized stress response associated with severe ill-
ness. However, whether the alterations of glucose 
metabolism that occur with a sudden onset in se-
vere Covid-19 persist or remit when the infection 
resolves is unclear. How frequent is the phenome-
non of new-onset diabetes, and is it classic type 1 
or type 2 diabetes or a new type of diabetes? Do 
these patients remain at higher risk for diabetes 
or diabetic ketoacidosis? In patients with preex-
isting diabetes, does Covid-19 change the under-
lying pathophysiology and the natural history of 
the disease? Answering these questions in order 
to inform the immediate clinical care, follow-up, 
and monitoring of affected patients is a priority.
To address these issues, an international group 
of leading diabetes researchers participating in 
the CoviDIAB Project have established a global 
registry of patients with Covid-19–related diabetes 
(covidiab . e - dendrite . com). The goal of the regis-
try is to establish the extent and phenotype of 
new-onset diabetes that is defined by hypergly-
cemia, confirmed Covid-19, a negative history of 
diabetes, and a history of a normal glycated he-
moglobin level. The registry, which will be ex-
panded to include patients with preexisting dia-
betes who present with severe acute metabolic 
disturbance, may also be used to investigate 
the epidemiologic features and pathogenesis of 
Covid-19–related diabetes and to gain clues re-
garding appropriate care for patients during and 
after the course of Covid-19. Given the very short 
history of human infection with SARS-CoV-2, an 
understanding of how Covid-19–related diabetes 
develops, the natural history of this disease, and 
appropriate management will be helpful. The study 
of Covid-19–related diabetes may also uncover 
novel mechanisms of disease.
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